BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29196963)

  • 1. Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
    Shien T; Doihara H; Sato N; Anan K; Komaki K; Miyauchi K; Yanagita Y; Fujisawa T; Mitsuyama S; Kanbayashi C; Kusama M; Kimura M; Jinno H; Sano M; Ikeda T
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):269-275. PubMed ID: 29196963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study.
    Anan K; Mitsuyama S; Yanagita Y; Kimura M; Doihara H; Komaki K; Kusama M; Ikeda T
    Breast Cancer Res Treat; 2011 Aug; 128(3):775-81. PubMed ID: 21638048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
    Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
    Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients.
    Marttunen MB; Hietanen P; Tiitinen A; Ylikorkala O
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1158-62. PubMed ID: 9543133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations.
    Kusama M; Kaise H; Nakayama S; Ota D; Misaka T; Aoki T
    Breast Cancer Res Treat; 2004 Nov; 88(1):9-16. PubMed ID: 15538041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
    Tominaga T; Kimijima I; Kimura M; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
    Jpn J Clin Oncol; 2010 Jul; 40(7):627-33. PubMed ID: 20382637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer.
    Joensuu H; Holli K; Oksanen H; Valavaara R
    Breast Cancer Res Treat; 2000 Oct; 63(3):225-34. PubMed ID: 11110056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
    Saarto T; Blomqvist C; Ehnholm C; Taskinen MR; Elomaa I
    J Clin Oncol; 1996 Feb; 14(2):429-33. PubMed ID: 8636753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
    Goss P; Bondarenko IN; Manikhas GN; Pendergrass KB; Miller WH; Langecker P; Blanchett D
    J Clin Oncol; 2007 Nov; 25(31):4961-6. PubMed ID: 17971594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
    Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
    J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].
    Lu HH; Li Q; Xu BH; Zhang P; Yuan P; Wang JY; Cai RG
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):520-5. PubMed ID: 22093630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
    Pyrhönen S; Ellmén J; Vuorinen J; Gershanovich M; Tominaga T; Kaufmann M; Hayes DF
    Breast Cancer Res Treat; 1999 Jul; 56(2):133-43. PubMed ID: 10573106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women.
    Cigler T; Richardson H; Yaffe MJ; Fabian CJ; Johnston D; Ingle JN; Nassif E; Brunner RL; Wood ME; Pater JL; Hu H; Qi S; Tu D; Goss PE
    Breast Cancer Res Treat; 2011 Apr; 126(2):453-61. PubMed ID: 21221773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study.
    Li Y; Deng Z; Wang Y; Shen S
    Lipids Health Dis; 2024 Jan; 23(1):9. PubMed ID: 38191454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
    Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer.
    Kimura M; Tominaga T; Kimijima I; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
    Breast Cancer; 2014 May; 21(3):275-83. PubMed ID: 22968626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients.
    Bertelli G; Queirolo P; Vecchio S; Angiolini C; Bergaglio M; Del Mastro L; Signorini A; Valenzano M; Venturini M
    Anticancer Res; 2000; 20(5C):3659-61. PubMed ID: 11268435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
    Cigler T; Tu D; Yaffe MJ; Findlay B; Verma S; Johnston D; Richardson H; Hu H; Qi S; Goss PE
    Breast Cancer Res Treat; 2010 Apr; 120(2):427-35. PubMed ID: 19967558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.